ClinicalTrials.gg
CompletedNCT03130959CheckMate 908Updated Aug 9, 2022Results posted

A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies

A Phase 2 interventional study of Nivolumab and Ipilimumab in Various Advanced Cancer, sponsored by Bristol-Myers Squibb. Completed at 54 sites in 15 countries. Open to participants aged 6 Months to 21 Years. Per ClinicalTrials.gov, last updated 2022-08-09.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
166
Allocation
Non-randomized
Ages
6 Months to 21 Years
Sex
All
01

Study summary

The purpose of this study is to determine the safety and effectiveness of nivolumab alone and in combination with ipilimumab in pediatric patients with high grade primary central nervous system (CNS) malignancies.

02

Conditions studied

  • Various Advanced Cancer
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have received standard of care therapy, and there must be no potentially-curative treatment available, in one of the following cohorts:
  • A newly diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) that has been treated with radiation therapy (RT) but no chemotherapy
  • A confirmed recurrent or progressive non-brainstem High Grade Glioma (HGG) previously treated with surgical resection and RT
  • A histologically confirmed medulloblastoma that has or is resistant to at least one including surgery, RT, and chemotherapy
  • A histologically confirmed ependymoma that has relapsed or is resistant to at least one line of prior therapy including surgical resection and RT
  • A histologically-confirmed high grade CNS "other than above" which is recurrent or progressive after at least one line of prior therapy
  • Lansky play score (LPS) for ≤ 16 years of age or performance scale (KPS) for > 16 years of age assessed within two weeks of enrollment must be >= 60
  • A tumor sample must be available for submission to central laboratory (not required for DIPG)

Exclusion criteria

Exclusion Criteria:

  • An active, known, or suspected disease
  • A concurrent condition requiring systemic treatment with either or other medications within 14 days of start of study treatment
  • Known history of positive test for (HIV) or known acquired immunodeficiency syndrome (AIDS).

Other protocol defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
166 participants (actual)

Study arms

  • Experimental
    Module A

    Biological: Nivolumab

  • Experimental
    Module B

    Biological: Nivolumab · Biological: Ipilimumab

Interventions

  • BiologicalNivolumab

    Specified dose on specified days

    Also known as: Opdivo, BMS-936558

  • BiologicalIpilimumab

    Specified dose on specified days

    Also known as: Yervoy, BMS-734016

06

What researchers measure

Primary outcomes

  1. Number of Safety Lead-In Participants With Dose Limiting Toxicities (DLTs)

    A dose-limiting toxicity (DLT) is defined as a drug-related AE occurring in the first 6 weeks of study treatment. A participant was considered evaluable for a DLT if study treatment was delayed \> 2 weeks or was discontinued due to a related Adverse Event (AE), or if planned study treatment (3 doses of nivolumab in Module A, 2 doses of nivolumab plus ipilimumab in Module B) was administered and safety evaluation after 6 weeks on study is available to the study steering committee (SSC).

    Time frame: up to 6 weeks post-dosing

  2. Number of Safety Lead-In Participants With Serious Adverse Events (SAEs)

    The number of Safety Lead-In Participants who experienced a Serious Adverse Event (SAE) during the course of the study.

    Time frame: up to 6 weeks post-dosing

  3. Number of Safety Lead-In Participants With Adverse Events (AEs) Leading to Discontinuation

    The number of Safety Lead-In Participants who experienced an Adverse Event (AE) during the course of the study that lead to discontinuation of study therapy.

    Time frame: From first dose to 30 days post-last dose (up to approximately 6 weeks)

  4. Overall Survival (OS), Cohort 1 Only

    Overall survival (OS) is defined as the time between the date of diagnosis and the date of death in Cohort 1.

    Time frame: up to approximately 42 months

  5. Progression-Free Survival (PFS), Cohorts 2-4

    Progression-free survival (PFS) is defined as the time from first dose to the date of the first documented tumor progression or death due to any cause.

    Time frame: up to approximately 42 months

  6. Progression-Free Survival (PFS), Cohort 5 Only

    Progression-free survival (PFS) is defined as the time from first dose to the date of the first documented tumor progression or death due to any cause.

    Time frame: up to approximately 42 months

Secondary outcomes

  1. Progression-Free Survival (PFS), Cohort 1 Only

    Progression-free survival (PFS) is defined as the time from first dose to the date of the first documented tumor progression or death due to any cause. Progression is defined as: * ≥ 25% increase in sum of the products of perpendicular diameters of enhancing lesions compared with the smallest tumor measurement * Significant increase in T2 or fast fluid-attenuated inversion recovery (FLAIR) non-enhancing lesions on stable or increasing doses of corticosteroids * Any new lesion * Clear clinical deterioration not attributable to other causes apart from the tumor * Failure to return for evaluation as a result of death or deteriorating condition * Clear progression of non-measurable disease

    Time frame: From first dose to the date of the first documented tumor progression or death due to any cause (up to approximately 55 months)

  2. Overall Survival at 12 Months (OS12), Cohorts 1-4

    Overall survival at 12 months (OS12) is defined as the percentage of participants who are alive at 12 months, measured as the survival rate at 12 months from Kaplan-Meier product limit cumulative probability.

    Time frame: From first dose to up to 12 months after first dose

  3. Progression-Free Survival at 6 Months (PFS6), Cohorts 2-5

    Progression-free survival at 6 months (PFS6) is defined as the percentage of participants who are progression free and alive at 6 months following first dose date, measured as the survival rate at 6 months from Kaplan-Meier product limit cumulative probability of progression free. Progression is defined as: * ≥ 25% increase in sum of the products of perpendicular diameters of enhancing lesions compared with the smallest tumor measurement * Significant increase in T2 or fast fluid-attenuated inversion recovery (FLAIR) non-enhancing lesions on stable or increasing doses of corticosteroids * Any new lesion * Clear clinical deterioration not attributable to other causes apart from the tumor * Failure to return for evaluation as a result of death or deteriorating condition * Clear progression of non-measurable disease

    Time frame: From first dose to up to 6 months after first dose

  4. Overall Survival (OS), Cohorts 2-5

    Overall survival (OS) is defined as the time between date of first dose and the date of death for Cohorts 2-5.

    Time frame: From first dose to the date of death (up to approximately 55 months)

  5. Number of Treated Participants With Adverse Events (AEs)

    The number of treated participants who experienced an Adverse Event (AE) during the course of the study. An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug.

    Time frame: From first dose to 30 days post-last dose (up to approximately an average of 3 months and a maximum of 51 months)

  6. Number of Treated Participants With Serious Adverse Events (SAEs)

    The number of treated participants who experienced a Serious Adverse Event (SAE) during the course of the study. SAE is defined as any untoward medical occurrence that, at any dose: * Results in death * Is life-threatening * Requires inpatient hospitalization or causes prolongation of existing hospitalization * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect * Is an important medical event Note: The reporting timeframe of the SAEs for this Outcome Measure (first dose to 30 days post last dose) differs than that of the reporting timeframe of the SAEs reported under the AE section of the results form (first dose to 100 days post last dose) and thus, the data in each table of SAEs reflects the specific timeframe applied.

    Time frame: From first dose to 30 days post-last dose (up to approximately an average of 3 months and a maximum of 51 months)

  7. Number of Treated Participants With Drug-Related Adverse Events

    The number of treated participants who experienced a Drug-Related Adverse Event during the course of the study. An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug.

    Time frame: From first dose to 30 days post-last dose (up to approximately an average of 3 months and a maximum of 51 months)

  8. Number of Treated Participants With Adverse Events Leading to Discontinuation

    The number of treated participants who experienced an Adverse Event leading to discontinuation during the course of the study. An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug.

    Time frame: From first dose to 30 days post-last dose (up to approximately an average of 3 months and a maximum of 51 months)

  9. Number of Treated Participant Deaths

    The number of treated participants who died during the course of the study.

    Time frame: From first dose to the date of death (up to approximately 55 months)

  10. Number of Treated Participant With Laboratory Abnormalities - Liver

    The number of treated participants who experienced a laboratory abnormality of the liver during the course of the study. Aspartate aminotransferase (AST) Alanine aminotransferase (ALT) Upper Limit of Normal (ULN) Units per Liter (U/L) Results reported in International System of Units (SI)

    Time frame: From first dose to 30 days post-last dose (up to approximately an average of 3 months and a maximum of 51 months)

  11. Number of Treated Participant With Laboratory Abnormalities - Thyroid

    The number of treated participants who experienced a laboratory abnormality of the thyroid during the course of the study. Free T3 (FT3) Free T4 (FT4) Thyroid stimulating hormone (TSH) Lower Limit of Normal (LLN) Upper limit of normal (ULN) Milliunits per Liter (mlU/L) Results reported in International System of Units (SI)

    Time frame: From first dose to 30 days post-last dose (up to approximately an average of 3 months and a maximum of 51 months)

07

Results

Posted Apr 1, 2021

Participant flow

Participant flow — Overall Study
MilestoneArm A1Arm B1Arm A2Arm B2Arm A3Arm B3Arm A4Arm B4Arm A5Arm B5
Started23221615151512101919
Completed01201090604
Not completed231016141561241915
Withdrew: Disease progression19712712363158
Withdrew: Study drug toxicity2212113033
Withdrew: Other reasons0000011000
Withdrew: Subject request to discontinue therapy0011001100
Withdrew: Not reported0001010001
Withdrew: Adverse event unrelated to drug0011101011
Withdrew: Participant withdrew consent0102100002
Withdrew: Administrative reason by sponsor1010000000
Withdrew: Lost to follow-up1000000000

Outcome measures

PrimaryNumber of Safety Lead-In Participants With Dose Limiting Toxicities (DLTs)

A dose-limiting toxicity (DLT) is defined as a drug-related AE occurring in the first 6 weeks of study treatment. A participant was considered evaluable for a DLT if study treatment was delayed \> 2 weeks or was discontinued due to a related Adverse Event (AE), or if planned study treatment (3 doses of nivolumab in Module A, 2 doses of nivolumab plus ipilimumab in Module B) was administered and safety evaluation after 6 weeks on study is available to the study steering committee (SSC).

Time frame:
up to 6 weeks post-dosing
Reported as:
Number · Number of participants
Number of Safety Lead-In Participants With Dose Limiting Toxicities (DLTs)
Number of participantsArm A1, Safety Lead-inArms A2-A5, Safety Lead-inArms B2-B5, Safety Lead-in
Number of Safety Lead-In Participants With Dose Limiting Toxicities (DLTs)000
PrimaryNumber of Safety Lead-In Participants With Serious Adverse Events (SAEs)

The number of Safety Lead-In Participants who experienced a Serious Adverse Event (SAE) during the course of the study.

Time frame:
up to 6 weeks post-dosing
Reported as:
Number · Number of participants
Number of Safety Lead-In Participants With Serious Adverse Events (SAEs)
Number of participantsArm A1, Safety Lead-inArms A2-A5, Safety Lead-inArms B2-B5, Safety Lead-in
Number of Safety Lead-In Participants With Serious Adverse Events (SAEs)768
PrimaryNumber of Safety Lead-In Participants With Adverse Events (AEs) Leading to Discontinuation

The number of Safety Lead-In Participants who experienced an Adverse Event (AE) during the course of the study that lead to discontinuation of study therapy.

Time frame:
From first dose to 30 days post-last dose (up to approximately 6 weeks)
Reported as:
Count of participants · Participants
Number of Safety Lead-In Participants With Adverse Events (AEs) Leading to Discontinuation
ParticipantsArm A1, Safety Lead-inArms A2-A5, Safety Lead-inArms B2-B5, Safety Lead-in
Number of Safety Lead-In Participants With Adverse Events (AEs) Leading to Discontinuation342
PrimaryOverall Survival (OS), Cohort 1 Only

Overall survival (OS) is defined as the time between the date of diagnosis and the date of death in Cohort 1.

Time frame:
up to approximately 42 months
Reported as:
Median · months
Overall Survival (OS), Cohort 1 Only
monthsArm A1Arm B1
Overall Survival (OS), Cohort 1 Only11.66 (10.32 to 16.46)10.78 (9.13 to 15.77)
PrimaryProgression-Free Survival (PFS), Cohorts 2-4

Progression-free survival (PFS) is defined as the time from first dose to the date of the first documented tumor progression or death due to any cause.

Time frame:
up to approximately 42 months
Reported as:
Median · months
Progression-Free Survival (PFS), Cohorts 2-4
monthsArm A2Arm B2Arm A3Arm B3Arm A4Arm B4
Progression-Free Survival (PFS), Cohorts 2-41.74 (1.35 to 2.73)1.31 (1.18 to 1.45)1.38 (1.22 to 1.38)2.76 (1.48 to 4.53)1.41 (1.41 to 2.60)4.60 (1.41 to 5.39)
PrimaryProgression-Free Survival (PFS), Cohort 5 Only

Progression-free survival (PFS) is defined as the time from first dose to the date of the first documented tumor progression or death due to any cause.

Time frame:
up to approximately 42 months
Reported as:
Median · months
Progression-Free Survival (PFS), Cohort 5 Only
monthsArm A5Arm B5
Progression-Free Survival (PFS), Cohort 5 Only1.22 (1.08 to 1.31)1.61 (1.31 to 3.45)
SecondaryProgression-Free Survival (PFS), Cohort 1 Only

Progression-free survival (PFS) is defined as the time from first dose to the date of the first documented tumor progression or death due to any cause. Progression is defined as: * ≥ 25% increase in sum of the products of perpendicular diameters of enhancing lesions compared with the smallest tumor measurement * Significant increase in T2 or fast fluid-attenuated inversion recovery (FLAIR) non-enhancing lesions on stable or increasing doses of corticosteroids * Any new lesion * Clear clinical deterioration not attributable to other causes apart from the tumor * Failure to return for evaluation as a result of death or deteriorating condition * Clear progression of non-measurable disease

Time frame:
From first dose to the date of the first documented tumor progression or death due to any cause (up to approximately 55 months)
Reported as:
Median · Months
Progression-Free Survival (PFS), Cohort 1 Only
MonthsArm A1Arm B1
Progression-Free Survival (PFS), Cohort 1 Only6.21 (3.75 to 6.54)4.53 (2.99 to 6.44)
SecondaryOverall Survival at 12 Months (OS12), Cohorts 1-4

Overall survival at 12 months (OS12) is defined as the percentage of participants who are alive at 12 months, measured as the survival rate at 12 months from Kaplan-Meier product limit cumulative probability.

Time frame:
From first dose to up to 12 months after first dose
Reported as:
Number · Percentage of participants
Overall Survival at 12 Months (OS12), Cohorts 1-4
Percentage of participantsArm A1Arm B1Arm A2Arm B2Arm A3Arm B3Arm A4Arm B4
Overall Survival at 12 Months (OS12), Cohorts 1-447.3 (25.2 to 66.5)42.9 (21.9 to 62.3)37.5 (15.4 to 59.8)32.8 (10.5 to 57.6)38.9 (14.3 to 63.2)86.7 (56.4 to 96.5)41.7 (15.2 to 66.5)44.4 (13.6 to 71.9)
SecondaryProgression-Free Survival at 6 Months (PFS6), Cohorts 2-5

Progression-free survival at 6 months (PFS6) is defined as the percentage of participants who are progression free and alive at 6 months following first dose date, measured as the survival rate at 6 months from Kaplan-Meier product limit cumulative probability of progression free. Progression is defined as: * ≥ 25% increase in sum of the products of perpendicular diameters of enhancing lesions compared with the smallest tumor measurement * Significant increase in T2 or fast fluid-attenuated inversion recovery (FLAIR) non-enhancing lesions on stable or increasing doses of corticosteroids * Any new lesion * Clear clinical deterioration not attributable to other causes apart from the tumor * Failure to return for evaluation as a result of death or deteriorating condition * Clear progression of non-measurable disease

Time frame:
From first dose to up to 6 months after first dose
Reported as:
Number · Percentage of participants
Progression-Free Survival at 6 Months (PFS6), Cohorts 2-5
Percentage of participantsArm A2Arm B2Arm A3Arm B3Arm A4Arm B4Arm A5Arm B5
Progression-Free Survival at 6 Months (PFS6), Cohorts 2-59.4 (0.7 to 31.8)14.3 (2.3 to 36.6)0 (NA to NA)20.0 (4.9 to 42.4)20.0 (3.1 to 47.5)11.4 (0.6 to 39.5)5.3 (0.4 to 21.4)14.0 (2.8 to 34.1)
SecondaryOverall Survival (OS), Cohorts 2-5

Overall survival (OS) is defined as the time between date of first dose and the date of death for Cohorts 2-5.

Time frame:
From first dose to the date of death (up to approximately 55 months)
Reported as:
Median · Months
Overall Survival (OS), Cohorts 2-5
MonthsArm A2Arm B2Arm A3Arm B3Arm A4Arm B4Arm A5Arm B5
Overall Survival (OS), Cohorts 2-56.67 (2.99 to 14.62)6.47 (2.14 to 13.17)7.36 (2.46 to 30.23)22.21 (13.77 to NA)5.70 (1.81 to NA)9.82 (2.50 to NA)5.91 (1.97 to 7.98)8.48 (3.45 to 17.28)
SecondaryNumber of Treated Participants With Adverse Events (AEs)

The number of treated participants who experienced an Adverse Event (AE) during the course of the study. An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug.

Time frame:
From first dose to 30 days post-last dose (up to approximately an average of 3 months and a maximum of 51 months)
Reported as:
Count of participants · Participants
Number of Treated Participants With Adverse Events (AEs)
ParticipantsArm A1Arm B1Arm A2Arm B2Arm A3Arm B3Arm A4Arm B4Arm A5Arm B5
Number of Treated Participants With Adverse Events (AEs)23211514141512101818
SecondaryNumber of Treated Participants With Serious Adverse Events (SAEs)

The number of treated participants who experienced a Serious Adverse Event (SAE) during the course of the study. SAE is defined as any untoward medical occurrence that, at any dose: * Results in death * Is life-threatening * Requires inpatient hospitalization or causes prolongation of existing hospitalization * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect * Is an important medical event Note: The reporting timeframe of the SAEs for this Outcome Measure (first dose to 30 days post last dose) differs than that of the reporting timeframe of the SAEs reported under the AE section of the results form (first dose to 100 days post last dose) and thus, the data in each table of SAEs reflects the specific timeframe applied.

Time frame:
From first dose to 30 days post-last dose (up to approximately an average of 3 months and a maximum of 51 months)
Reported as:
Count of participants · Participants
Number of Treated Participants With Serious Adverse Events (SAEs)
ParticipantsArm A1Arm B1Arm A2Arm B2Arm A3Arm B3Arm A4Arm B4Arm A5Arm B5
Number of Treated Participants With Serious Adverse Events (SAEs)101410967751314
SecondaryNumber of Treated Participants With Drug-Related Adverse Events

The number of treated participants who experienced a Drug-Related Adverse Event during the course of the study. An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug.

Time frame:
From first dose to 30 days post-last dose (up to approximately an average of 3 months and a maximum of 51 months)
Reported as:
Count of participants · Participants
Number of Treated Participants With Drug-Related Adverse Events
ParticipantsArm A1Arm B1Arm A2Arm B2Arm A3Arm B3Arm A4Arm B4Arm A5Arm B5
Number of Treated Participants With Drug-Related Adverse Events1416128611661110
SecondaryNumber of Treated Participants With Adverse Events Leading to Discontinuation

The number of treated participants who experienced an Adverse Event leading to discontinuation during the course of the study. An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug.

Time frame:
From first dose to 30 days post-last dose (up to approximately an average of 3 months and a maximum of 51 months)
Reported as:
Count of participants · Participants
Number of Treated Participants With Adverse Events Leading to Discontinuation
ParticipantsArm A1Arm B1Arm A2Arm B2Arm A3Arm B3Arm A4Arm B4Arm A5Arm B5
Number of Treated Participants With Adverse Events Leading to Discontinuation4735236168
SecondaryNumber of Treated Participant Deaths

The number of treated participants who died during the course of the study.

Time frame:
From first dose to the date of death (up to approximately 55 months)
Reported as:
Count of participants · Participants
Number of Treated Participant Deaths
ParticipantsArm A1Arm B1Arm A2Arm B2Arm A3Arm B3Arm A4Arm B4Arm A5Arm B5
Number of Treated Participant Deaths181812131211971815
SecondaryNumber of Treated Participant With Laboratory Abnormalities - Liver

The number of treated participants who experienced a laboratory abnormality of the liver during the course of the study. Aspartate aminotransferase (AST) Alanine aminotransferase (ALT) Upper Limit of Normal (ULN) Units per Liter (U/L) Results reported in International System of Units (SI)

Time frame:
From first dose to 30 days post-last dose (up to approximately an average of 3 months and a maximum of 51 months)
Reported as:
Count of participants · Participants
Number of Treated Participant With Laboratory Abnormalities - Liver
ParticipantsArm A1Arm B1Arm A2Arm B2Arm A3Arm B3Arm A4Arm B4Arm A5Arm B5
ALT OR AST > 3XULN3720031132
ALT OR AST > 5XULN2410010122
ALT OR AST > 10XULN2110010122
ALT OR AST > 20XULN0110000002
TOTAL BILIRUBIN > 2XULN0200000011
ALP > 1.5XULN000—————01
ALT or AST > 3xULN w/ Tbili > 1.5*ULN within 1 day0110000001
ALT or AST > 3xULN w/ Tbili > 1.5*ULN within 30 days0210000001
ALT or AST > 3xULN w/ Tbili > 2*ULN within 1 day0100000001
ALT or AST > 3xULN w/ Tbili > 2*ULN within 30 days0200000001
SecondaryNumber of Treated Participant With Laboratory Abnormalities - Thyroid

The number of treated participants who experienced a laboratory abnormality of the thyroid during the course of the study. Free T3 (FT3) Free T4 (FT4) Thyroid stimulating hormone (TSH) Lower Limit of Normal (LLN) Upper limit of normal (ULN) Milliunits per Liter (mlU/L) Results reported in International System of Units (SI)

Time frame:
From first dose to 30 days post-last dose (up to approximately an average of 3 months and a maximum of 51 months)
Reported as:
Count of participants · Participants
Number of Treated Participant With Laboratory Abnormalities - Thyroid
ParticipantsArm A1Arm B1Arm A2Arm B2Arm A3Arm B3Arm A4Arm B4Arm A5Arm B5
TSH > ULN2131372315
TSH > ULN, WITH TSH <= ULN AT BASELINE2121071312
TSH > ULN, WITH AT LEAST ONE FT3/FT4 TEST < LLN1111162202
TSH > ULN, WITH ALL OTHER FT3/FT4 TEST >= LLN0010000013
TSH > ULN, WITH FT3/FT4 TEST MISSING1010210100
TSH < LLN3722030001
TSH < LLN, WITH TSH >= LLN AT BASELINE3612010001
TSH<LLN, LLN WITH AT LEAST ONE FT3/FT4 TEST>ULN0100020000
TSH < LLN, WITH ALL OTHER FT3/FT4 TEST <= ULN1212010001
TSH < LLN, WITH FT3/FT4 TEST MISSING2410000000
Post-hocOverall Survival (OS), Cohort 1 Only - Extended Collection

Overall survival (OS) is defined as the time between the date of diagnosis and the date of death in Cohort 1. Note: This outcome measure represents an updated version of the primary endpoint to include additional data collection that has occurred after the primary completion date. (Assessments were made until 17-Jan-2022).

Time frame:
From first dose to the date of death (up to approximately 55 months)
Reported as:
Median · Months
Overall Survival (OS), Cohort 1 Only - Extended Collection
MonthsArm A1Arm B1
Overall Survival (OS), Cohort 1 Only - Extended Collection11.66 (10.32 to 23.49)10.78 (9.13 to 15.77)
Post-hocProgression-Free Survival (PFS), Cohorts 2-4 - Extended Collection

Progression-free survival (PFS) is defined as the time from first dose to the date of the first documented tumor progression or death due to any cause. Note: This outcome measure represents an updated version of the primary endpoint to include additional data collection that has occurred after the primary completion date. (Assessments were made until 17-Jan-2022). Progression is defined as: * ≥ 25% increase in sum of the products of perpendicular diameters of enhancing lesions compared with the smallest tumor measurement * Significant increase in T2 or fast fluid-attenuated inversion recovery (FLAIR) non-enhancing lesions on stable or increasing doses of corticosteroids * Any new lesion * Clear clinical deterioration not attributable to other causes apart from the tumor * Failure to return for evaluation as a result of death or deteriorating condition * Clear progression of non-measurable disease

Time frame:
From first dose to the date of the first documented tumor progression or death due to any cause (up to approximately 55 months)
Reported as:
Median · Months
Progression-Free Survival (PFS), Cohorts 2-4 - Extended Collection
MonthsArm A2Arm B2Arm A3Arm B3Arm A4Arm B4
Progression-Free Survival (PFS), Cohorts 2-4 - Extended Collection1.74 (1.35 to 2.73)1.38 (1.22 to 1.48)1.38 (1.22 to 1.38)2.69 (1.48 to 4.53)1.41 (1.38 to 2.60)4.60 (1.41 to 5.39)
Post-hocProgression-Free Survival (PFS), Cohort 5 Only - Extended Collection

Progression-free survival (PFS) is defined as the time from first dose to the date of the first documented tumor progression or death due to any cause. Note: This outcome measure represents an updated version of the primary endpoint to include additional data collection that has occurred after the primary completion date. (Assessments were made until 17-Jan-2022). Progression is defined as: * ≥ 25% increase in sum of the products of perpendicular diameters of enhancing lesions compared with the smallest tumor measurement * Significant increase in T2 or fast fluid-attenuated inversion recovery (FLAIR) non-enhancing lesions on stable or increasing doses of corticosteroids * Any new lesion * Clear clinical deterioration not attributable to other causes apart from the tumor * Failure to return for evaluation as a result of death or deteriorating condition * Clear progression of non-measurable disease

Time frame:
From first dose to the date of the first documented tumor progression or death due to any cause (up to approximately 55 months)
Reported as:
Median · Months
Progression-Free Survival (PFS), Cohort 5 Only - Extended Collection
MonthsArm A5Arm B5
Progression-Free Survival (PFS), Cohort 5 Only - Extended Collection1.22 (1.08 to 1.31)1.61 (1.31 to 3.45)

Adverse events

Collected over All-cause mortality was assessed from first dose to study completion (up to approximately 55 months). SAEs and Other AEs were monitored from first dose to 100 days after last dose (up to an average of 5 months and to a maximum of 53 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A118/23 (78.3%)17/23 (73.9%)22/23 (95.7%)
Arm B118/22 (81.8%)16/22 (72.7%)21/22 (95.5%)
Arm A212/16 (75%)13/16 (81.3%)15/16 (93.8%)
Arm B213/15 (86.7%)12/15 (80%)14/15 (93.3%)
Arm A312/15 (80%)7/15 (46.7%)14/15 (93.3%)
Arm B311/15 (73.3%)10/15 (66.7%)14/15 (93.3%)
Arm A49/12 (75%)11/12 (91.7%)11/12 (91.7%)
Arm B47/10 (70%)6/10 (60%)10/10 (100%)
Arm A518/19 (94.7%)14/19 (73.7%)18/19 (94.7%)
Arm B515/19 (78.9%)15/19 (78.9%)18/19 (94.7%)
Most frequent serious events
Showing 10 of 103
Most frequent serious events
EventArm A1Arm B1Arm A2Arm B2Arm A3Arm B3Arm A4Arm B4Arm A5Arm B5
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)9/237/226/165/156/152/157/125/107/197/19
HydrocephalusNervous system disorders0/234/221/160/151/150/153/122/101/191/19
PyrexiaGeneral disorders0/230/221/161/150/150/151/122/101/192/19
HeadacheNervous system disorders1/232/220/162/151/151/151/122/101/192/19
NauseaGastrointestinal disorders0/230/220/160/150/150/152/121/100/190/19
VomitingGastrointestinal disorders0/233/221/162/150/151/152/121/101/191/19
Tumour flareNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/233/220/161/150/150/150/120/100/190/19
ColitisGastrointestinal disorders0/231/220/160/150/152/150/120/100/190/19
Device related infectionInfections and infestations0/230/220/160/150/150/150/120/101/192/19
Intracranial pressure increasedNervous system disorders0/230/221/161/151/150/150/120/102/191/19
Most frequent other events
Showing 10 of 361
Most frequent other events
EventArm A1Arm B1Arm A2Arm B2Arm A3Arm B3Arm A4Arm B4Arm A5Arm B5
HeadacheNervous system disorders9/2310/227/162/157/156/155/122/1013/195/19
VomitingGastrointestinal disorders8/2311/227/164/154/153/155/124/108/1910/19
NauseaGastrointestinal disorders8/234/224/164/151/153/154/121/103/195/19
FatigueGeneral disorders8/236/224/163/152/154/152/121/105/194/19
ConstipationGastrointestinal disorders5/235/225/165/150/153/151/122/105/194/19
Aspartate aminotransferase increasedInvestigations2/234/222/162/151/155/151/121/104/191/19
Abdominal painGastrointestinal disorders4/237/222/161/152/153/151/120/105/194/19
Weight decreasedInvestigations3/237/221/160/152/151/151/120/100/192/19
HemiparesisNervous system disorders4/237/220/160/150/150/150/121/101/190/19
HypophosphataemiaMetabolism and nutrition disorders1/230/221/160/151/150/150/120/106/190/19

Baseline characteristics

Age, Customized
Age, Customized(Participants)Arm A1Arm B1Arm A2Arm B2Arm A3Arm B3Arm A4Arm B4Arm A5Arm B5Total
< 2 years old00000001113
>= 2 and < 12 years old1516654484131287
>= 12 and < 18 years old6568119334661
>= 18 years old214202121015
Sex: Female, Male
Sex: Female, Male(Participants)Arm A1Arm B1Arm A2Arm B2Arm A3Arm B3Arm A4Arm B4Arm A5Arm B5Total
Female121663556341070
Male116101210106715996
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A1Arm B1Arm A2Arm B2Arm A3Arm B3Arm A4Arm B4Arm A5Arm B5Total
Hispanic or Latino232201112014
Not Hispanic or Latino7104564558660
Unknown or Not Reported1491089106491392
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Arm A1Arm B1Arm A2Arm B2Arm A3Arm B3Arm A4Arm B4Arm A5Arm B5Total
White191113141414791813132
Black or African American24000110109
Asian021100310210
American Indian or Alaska Native01000000001
Native Hawaiian or Other Pacific Islander00000000000
Other242010100414
08

Study locations

54 sites
  • Local Institution - 0057
    Los Angeles, California 90027, United States
  • Local Institution - 0016
    Aurora, Colorado 80045, United States
  • Local Institution - 0046
    Gainesville, Florida 32611, United States
  • Local Institution - 0011
    Chicago, Illinois 60611-2605, United States
  • Local Institution - 0005
    Baltimore, Maryland 21287, United States
  • Local Institution - 0043
    Boston, Massachusetts 02215, United States
  • Local Institution - 0044
    Saint Louis, Missouri 63110, United States
  • Local Institution - 0004
    New York, New York 10021, United States
  • Local Institution - 0017
    New York, New York 10032, United States
  • Cincinnati Children'S Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Local Institution - 0066
    Philadelphia, Pennsylvania 19104, United States
  • Local Institution
    Charleston, South Carolina 29425, United States
  • Local Institution - 0012
    Memphis, Tennessee 38105, United States
  • Local Institution - 0042
    Houston, Texas 77030, United States
  • Local Institution - 0022
    Randwick, New South Wales 2031, Australia
  • Local Institution - 0035
    Sth Brisbane, Queensland 4101, Australia
  • Local Institution
    Clayton, Victoria 3168, Australia
  • Local Institution - 0034
    Parkville, Victoria 3052, Australia
  • Local Institution - 0033
    Nedlands, Western Australia 6009, Australia
  • Local Institution - 0052
    Porto Alegre, RIO Grande DO SUL 90035-074, Brazil
  • Local Institution - 0051
    Barretos, Sao Paulo 14784-400, Brazil
  • Local Institution - 0053
    Ribeirao Preto, Sao Paulo 14048-900, Brazil
  • Local Institution - 0049
    Sao Paulo, 04023-062, Brazil
  • Local Institution - 0050
    Sao Paulo, 08270-070, Brazil
  • Local Institution - 0021
    Toronto, Ontario M5G 1X8, Canada
  • Local Institution - 0001
    Montreal, Quebec H4A 3J1, Canada
  • Local Institution - 0002
    Quebec, G1V 4G2, Canada
  • Local Institution - 0028
    Angers, 49100, France
  • Local Institution - 0029
    Bordeaux Cedex, 33076, France
  • Local Institution - 0027
    Lille, 59000, France
  • Local Institution - 0025
    Lyon, 69008, France
  • Local Institution - 0024
    Marseille, 13385 cedex 05, France
  • Local Institution - 0023
    Paris, 75231 cedex 5, France
  • Local Institution - 0064
    Vandoeuvre les Nancy, 54500, France
  • Local Institution - 0026
    VIillejuif, 94805 CEDEX, France
  • Local Institution - 0060
    Essen, 45147, Germany
  • Local Institution - 0061
    Hamburg, 20246, Germany
  • Local Institution - 0063
    Heidelberg, 69120, Germany
  • Local Institution - 0062
    Wuerzburg, 97080, Germany
  • Local Institution - 0018
    Hong Kong, 852, Hong Kong
  • Local Institution - 0059
    Haifa, 3109601, Israel
  • Local Institution - 0058
    Ramat Gan, 5266202, Israel
  • Local Institution - 0007
    Rotterdam, 3015 GJ, Netherlands
  • Local Institution - 0008
    Utrecht, 3584 EA, Netherlands
  • Local Institution - 0067
    Oslo, 0027, Norway
  • Local Institution - 0047
    Warszawa, 04-730, Poland
  • Local Institution - 0048
    Moscow, 117997, Russian Federation
  • Local Institution - 0037
    Esplugues de Llobregat, 08950, Spain
  • Local Institution - 0038
    Madrid, 28009, Spain
  • Local Institution - 0036
    Valencia, 46026, Spain
  • Local Institution - 0065
    Solna, 171 76, Sweden
  • Local Institution - 0010
    London, Greater London WC1N 3JH, United Kingdom
  • Local Institution - 0013
    Liverpool, Merseyside L12 2AP, United Kingdom
  • Local Institution - 0015
    Newcastle Upon Tyne, Tyne And Wear NEI 4LP, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2017 to primary completion in Mar 2020, 32 months.

Results were first posted in Apr 2021, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2017
First posted
Apr 27, 2017
StartActual
Jun 12, 2017
Primary completionActual
Mar 10, 2020
CompletionActual
Jan 17, 2022
Results first posted
Apr 1, 2021
Last update
Aug 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03130959
Responsible party
Sponsor
First posted
Apr 27, 2017
Start date
Jun 12, 2017
Primary completion
Mar 10, 2020
Completion
Jan 17, 2022
Results posted
Apr 1, 2021
Last update
Aug 9, 2022

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Ipilimumab

Start the discussion